01:22 , Feb 10, 2018 |  BioCentury  |  Finance

Foundation validation

The not-for-profit Cystic Fibrosis Foundation is putting its weight behind a new approach to treating CF through a $25 million award to Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP). Corbus plans to use the award to validate...
12:08 , May 24, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A panel of oncogenic gene fusions in tumors could provide new therapeutic targets for colorectal cancer. Transcriptome sequencing of stage I-III primary tumors and matched healthy colon tissue from 278 colorectal cancer...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); BRAF; ES cell expressed Ras (ERAS)

Cancer INDICATION: Melanoma In vitro studies suggest AKT inhibitors could help treat tumors with ERAS-driven resistance to BRAF inhibitors. In a mouse model of BRAF-mutant melanoma, insertional transposon mutagenesis identified ERAS mutations in tumors that...
07:00 , Oct 10, 2011 |  BioCentury  |  Product Development

Gleevec in PAH

Phase III data for Novartis AG 's Gleevec imatinib show potential for the tyrosine kinase inhibitor in late-stage pulmonary arterial hypertension. But its second-generation TKI Tasigna nilotinib could do even better and has more patent...
07:00 , Aug 29, 2011 |  BioCentury  |  Finance

Short of breath

Short of breath United Therapeutics Corp. (NASDAQ:UTHR) fell $8.85 (18%) to $39.91 on Wednesday after its oral treprostinil again failed to beat placebo in a Phase III trial as an add-on therapy for pulmonary arterial...
07:00 , Mar 14, 2011 |  BioCentury  |  Strategy

Letairis LEAPS Forward

Letairis ambrisentan was the driver of Gilead Sciences Inc. $2.5 billion cash acquisition of Myogen Inc. in 2006. But like Tracleer bosentan from Actelion Ltd. , Letairis ended up with a boxed warning about the...
08:00 , Jan 31, 2008 |  BC Innovations  |  Targets & Mechanisms

Tumors lose their privileges

A key challenge for cancer vaccine development is the ability of tumors to evade the immune system. Research published by a group at the University of Pennsylvania identified a key target in the process-the endothelin...